Strategic Partners


Carmel Biosciences plans to further expand its existing and developing pipelines by utilizing the scientific expertise of its team to create novel products and by obtaining licensing rights for compounds with patent protection from its network of universities and other start-up drug development companies. Enabled by our extensive global network, the Carmel Biosciences business model has rapidly identified promising formulations of known compound entities. The typical cost of such projects using our business model is significantly below “traditional” development models and has the further advantage of accelerating speed to market.

The extensive personal and professional network developed by the founders allows the opportunity to perform this development in an expedited process that will also involve a reduction in development costs. Central to the business model is the continuous cycle of identification and development of lead compound(s) through clinical trials, licensing agreements with arger pharmaceutical companies, and using monies from agreements and royalties to develop successive, successful entities.

Investor Relations

Carmel Biosciences’ strategy is to identify and evaluate novel formulations of known components and contribute value-added processes to bring drugs and nutraceuticals to rapid commercialization. Revenue and profit opportunities are created due to the company’s proprietary patents and access to new licensing deals through the global network of the management. The financial strategy is that known components permit fast development through multiple projects, as well as fast licensing. We have limited fixed overhead with variable expenses and scalable organization (both up and down).

Carmel Biosciences’ management team has proven ability to execute the strategy of identifying and evaluating novel formulations then contributing value-added processes to bring products through clinical trials to licensing.

Why Invest In Carmel?

Proven track record for discovering novel compounds that can be rapidly commercialized to quickly generate revenue

Unique solutions to shorten the pathway for critical R&D milestone decisions and planning through its talented organization and strong international network

Immediate formulation and marketing of a nutraceutical product for a high demand indications - generating revenue at an early stage

Generate an IND from its drug discovery program within seven months of candidate selection for accelerated human studies.  This would result in an attractive model for strong clinical data with efficiency, cost-effectiveness and low involvement for internal resources

Creative Options For Enhancing R&D Productivity By:

Evaluating academic/external intellectual property to a decision point

Focusing on diseases with high need therapy

Repurposing existing drugs and/or discontinued molecules; and extending the bandwidth for internal R & D priorities